rs146795390
Variant summary
Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PM1PP3PP5
The NM_005228.5(EGFR):c.2527G>A(p.Val843Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000372 in 1,613,922 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. V843V) has been classified as Likely benign.
Frequency
Consequence
NM_005228.5 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152092Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000796 AC: 2AN: 251282 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461830Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727214 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152092Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74284 show subpopulations
ClinVar
Submissions by phenotype
Lung cancer Pathogenic:1
The EGFR exon 21 V843I mutation is located in the EGFR tyrosine kinase domain. This mutation has been identified as a germline variant that predisposes patients to lung cancer (PMID: 23380224, 21172876, 18355544)(Abstract: Ohtsuka et al. JCO PO, 2019.). Cell line experiments demonstrate that this mutation is activating, transforming and resistant to EGFR tyrosine kinase inhibitors (TKIs) (PMID: 25057940, 23380224, 21172876, 18355544). Despite cell line data demonstrating that V843I confers resistance to EGFR TKIs (PMID: 25057940, 23380224, 21172876, 18355544), in two clinical studies, three patients with non-small cell lung cancer (NSCLC) harboring the EGFR V843I mutation alone or in combination with the erlotinib- and gefitinib-sensitive EGFR L858R mutation had a partial response (one of three) or stable disease (two of three) upon treatment with gefitinib (PMID: 18000506, 19536777). -
EGFR-related lung cancer Uncertain:1
This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 843 of the EGFR protein (p.Val843Ile). This variant is present in population databases (rs146795390, gnomAD 0.0009%). This missense change has been observed in individual(s) with lung cancer (PMID: 18355544, 21172876, 23380224, 25176975, 34012789). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 376212). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt EGFR protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects EGFR function (PMID: 25057940). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at